CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer

Dae-Won Lee, Yoojoo Lim, Hwang-Phill Kim, Su Yeon Kim, Hanseong Roh, Jun-Kyu Kang, Kyung‑Hun Lee, Min Jung Kim, Seung-Bum Ryoo, Ji Won Park, Seung-Yong Jeong, Kyu Joo Park, Gyeong Hoon Kang, Sae-Won Han, Tae-You Kim

Cancer Research and Treatment. 2023;55(3):927-938. Published online 2023 March 7 DOI: https://doi.org/10.4143/crt.2023.268

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer

Cancer Research and Treatment. 2023;55(3):927-938

Link1

Link2 Link3

Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer

Giovanni Germano, Gianluca Mauri, Giulia Siravegna, Caroline Dive, Jackie Pierce, Federica Di Nicolantonio, Maurizio D'Incalci, Alberto Bardelli, Salvatore Siena, Andrea Sartore-Bianchi

Clinical Colorectal Cancer. 2018;17(1):80-83

Link1 Link2

2013 Analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): Correlation with clinical outcome

M. Teufel, J. Kalmus, M. Rutstein, K. Köchert, H. Seidel, J. Reischl, A. Skubula, R. Vonk, S. Wilhelm, S. Kobina, S. Qin, R. Xu, T.W. Kim, J. Li

European Journal of Cancer. 2015;51:S332

Link1 Link2

Circulating DNA and Protein Biomarkers for the Treatment of Metastatic Colorectal Cancer with Tyrosine Kinase Inhibitors

Kjetil Søreide

Oncogenomics. 2019;271-285

Link1 Link2

386P Methylated circulating tumor DNA in plasma as a biomarker for treatment efficacy in metastatic colorectal cancer

L. Raunkilde, T.F. Hansen, R.F. Andersen, L.H. Jensen

Annals of Oncology. 2022;33:S713

Link1 Link2

Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer

Yoshiaki Nakamura, Takayuki Yoshino

The Oncologist. 2018;23(11):1310-1318

Link1 Link2 Link3

Link4

Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons

Carlyn Rose C. Tan, Lanlan Zhou, Wafik S. El-Deiry

Current Colorectal Cancer Reports. 2016;12(3):151-161

Link1

Link2 Link3

Predictive Value of Early Tumor Shrinkage and Density Reduction of Lung Metastases in Patients With Metastatic Colorectal Cancer Treated With Regorafenib

Hannes Vanwynsberghe, Xander Verbeke, Johan Coolen, Eric Van Cutsem

Clinical Colorectal Cancer. 2017;16(4):377-380

Link1 Link2

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer

Chongkai Wang, Dawnyel Chevalier, Janelle Saluja, Jaideep Sandhu, Cecilia Lau, Marwan Fakih

The Oncologist. 2020;25(8):e1188-e1194

Link1 Link2 Link3 Link4

Link5

Correction to: Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA

Giorgio Patelli, Caterina Vaghi, Federica Tosi, Gianluca Mauri, Alessio Amatu, Daniela Massihnia, Silvia Ghezzi, Erica Bonazzina, Katia Bencardino, Giulio Cerea, Salvatore Siena, Andrea Sartore-Bianchi

Targeted Oncology. 2021;16(3):413-413

Link1

Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.